TY - JOUR
T1 - Economic evaluation of Medically Assisted Reproduction
T2 - An educational overview of methods and applications for healthcare professionals
AU - Luyten, Jeroen
AU - Connolly, Mark P.
AU - Verbeke, Evelyn
AU - Buhler, Klaus
AU - Scotland, Graham
AU - Lispi, Monica
AU - Revelli, Alberto
AU - Borget, Isabelle
AU - Cedrin-Durnerin, Isabelle
AU - D'Hooghe, Thomas
N1 - Funding Information:
This study was funded by Merck (CrossRef Funder ID: 10.13039/100009945 ). Merck Healthcare KGaA (Darmstadt, Germany) designed and approved the study, took part in data collection and data analysis, and contributed to the data interpretation and final draft of the manuscript.
Funding Information:
Medical writing support was provided by Steven Goodrick of inScience Communications, Springer Healthcare Ltd, UK, and was funded by Merck Healthcare KGaA, Darmstadt, Germany.
Publisher Copyright:
© 2022 The Authors
PY - 2022/12
Y1 - 2022/12
N2 - Economic evaluations of the value-for-money of Medically Assisted Reproduction (MAR) interventions are increasingly important due to growing pressure on healthcare budgets. Although such evaluations are commonplace in the published literature, the number/methodological complexity of different evaluations available, and the challenges specific to MAR interventions, can complicate the interpretation of such analyses for fertility treatments. This article aims to serve as an educational resource and provide context on the design/interpretation of economic analyses for MAR interventions. Several areas are relevant for first-line providers and decision makers: scope of analysis, comparator used, perspective/time horizon considered, outcomes used to measure success, and how results from cost-effectiveness studies can be summarised and used in clinical practice. We aim to help clinicians better understand the strengths/weaknesses of economic analyses, to enable the best use of the evidence in practice, so resources available for MAR interventions can provide maximum value to patients and society.
AB - Economic evaluations of the value-for-money of Medically Assisted Reproduction (MAR) interventions are increasingly important due to growing pressure on healthcare budgets. Although such evaluations are commonplace in the published literature, the number/methodological complexity of different evaluations available, and the challenges specific to MAR interventions, can complicate the interpretation of such analyses for fertility treatments. This article aims to serve as an educational resource and provide context on the design/interpretation of economic analyses for MAR interventions. Several areas are relevant for first-line providers and decision makers: scope of analysis, comparator used, perspective/time horizon considered, outcomes used to measure success, and how results from cost-effectiveness studies can be summarised and used in clinical practice. We aim to help clinicians better understand the strengths/weaknesses of economic analyses, to enable the best use of the evidence in practice, so resources available for MAR interventions can provide maximum value to patients and society.
KW - Assisted reproduction
KW - Cost-effectiveness analysis
KW - Economic evaluation
KW - Fertility treatment
U2 - 10.1016/j.bpobgyn.2022.01.008
DO - 10.1016/j.bpobgyn.2022.01.008
M3 - Review article
C2 - 35219590
AN - SCOPUS:85125501046
SN - 1521-6934
VL - 85
SP - 217
EP - 228
JO - Best Practice and Research: Clinical Obstetrics and Gynaecology
JF - Best Practice and Research: Clinical Obstetrics and Gynaecology
ER -